Major Depressive Disorder | Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Major Depressive Disorder research study

What is the primary objective of this study?

This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.

Who is eligible to participate?

Inclusion Criteria: Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to menopause prescribed with desvenlafaxine succinate Exclusion Criteria: Hypersensitivity to desvenlafaxine succinate

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Major Depressive Disorder

Vasomotor Symptoms

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:desvenlafaxine succinate50 mg tablet once daily

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.


Study Status


Start Date: March 2012

Completed Date: August 2012


Type: Observational


Primary Outcome: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs)

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Pfizer Call Center

Lead Sponsor: Pfizer


More information:

Discuss Pristiq